Kyowa Hakko Kogyo Subsidiary Licenses Antibody Technology To U.S. Biotech
This article was originally published in PharmAsia News
BioWa, Kyowa Hakko Kogyo's wholly owned U.S. subsidiary, licensed its Complegent antibody technology to Medarex, a U.S. bioventure. The technology involves combining parts of two antibody classes to make an antibody 10 times more efficacious. Medarex becomes the first biotech to license the technology from BioWa and is collaborating with Kirin Pharma to develop antibody drugs. Kirin is to merge with Kyowa Hakko later this year. (Click here for more - a subscription may be required
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.